Health Condition 1: A318- Other mycobacterial infections
Conditions
Interventions
None listed
Sponsors
Pfizer
Eligibility
Inclusion criteria
Inclusion criteria: Patients eligible to be enrolled are adults meeting both of the following criteria during the study period of 8â??14 months (depending on the site start date and minimum number of patients to be enrolled at the site): Hospitalised adult patients (>=18 years) confirmed to have an infection caused by any of the following most important hospital and community bacterial and fungal pathogens of interest: - Enterobacterales: primarily Citrobacter, Enterobacter, Escherichia, Klebsiella, Morganella, Proteus, Providencia, Salmonella, Serratia, Shigella - Acinetobacter spp. - Pseudomonas spp. - Staphylococcus spp. - Streptococcus spp. - Enterococcus spp. - Bacteroides spp. - Clostridium spp. - Haemophilus influenzae, ampicillin-resistant - Mucorales: primarily Cunninghamella, Mucor, Rhizopus, Rhizomucor, Syncephalastraceae - Candida spp. - Aspergillus spp. - Fusarium spp. - Scedosporium spp. - Lomentospora spp. - Cryptococcus spp. Isolates will have been tested for antimicrobial susceptibility using the site laboratoryâ??s routine methodology. ï?· Hospitalised adult patients (>=18 years) with a diagnosis of any of the following bacterial or fungal infections: - IAI - UTI - SSSI - LRTI, including CAP, HAP and VAP - BSI, including primary, secondary and catheter-related - CNS infections (according to the Institutionâ??s algorithms for diagnosis).
Exclusion criteria
Exclusion criteria: Patients meeting any of the following criteria will not be included in the study: Where data are collected retrospectively, patients admitted before 25 February 2015. Patients enrolled in any clinical trial of a new chemical entity (NCE) antimicrobial agent Patients with isolates meeting any of the following criteria will not be included in the study: - Duplicate isolates (same species) obtained from the same or different anatomical sites of the same patient. - Isolates from vigilance (surveillance) swabs. - Isolates that are considered contaminants. - Isolates from in-situ drains or drainage bottles.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Admission:- COVID-19 status Discharge:- COVID-19 status Life status, incl infection-related mortality Discharge: diagnoses (1° and 2°), destination (e.g. home, ward), admission / discharge dates, Days in ICU Resouce utilisation, incl antibiotic use Clinical outcome: Cure / Indeterminate / Failure Surgical (theatre) interventions - diagnostic/therapeutic Microbiological outcome: Presumed Eradication / Microbiological FailureTimepoint: This is â??an observational study where we are unable to be prescriptive about timepoints, the timepoints for collection of the outcome data were determined based on â??fixed eventsâ?? of admission and discharge.â?? | — |
Secondary
| Measure | Time frame |
|---|---|
| Not ApplicableTimepoint: Not Applicable | — |
Countries
India, Mexico, Saudi Arabia, Spain, United Kingdom
Contacts
Public ContactDr Murali Chakravarthy
Fortis Hospital, Bannerghatta Road
Outcome results
None listed